Virios Therapeutics Reports on Shareholder Vote

TL;DR

Virios shareholders voted on something important June 18th. Details in the 8-K.

AI Summary

Virios Therapeutics, Inc. filed an 8-K on June 20, 2024, reporting on a matter submitted to a vote of security holders on June 18, 2024. The filing details the company's corporate information, including its incorporation in Delaware and its principal executive offices located at 44 Milton Avenue, Alpharetta, GA 30009.

Why It Matters

This filing indicates a significant event where shareholders voted on a matter, which could impact the company's future direction or governance.

Risk Assessment

Risk Level: low — This is a routine filing reporting on a shareholder vote, not indicating immediate financial distress or significant operational changes.

Key Players & Entities

• Virios Therapeutics, Inc. (company) — Registrant
• June 18, 2024 (date) — Date of earliest event reported
• June 20, 2024 (date) — Date of report
• 44 Milton Avenue, Alpharetta, GA 30009 (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 VIRI Nasdaq Capital Market Check t

Filing Documents

• viri-20240618x8k.htm (8-K) — 63KB
• 0001558370-24-009327.txt ( ) — 181KB
• viri-20240618.xsd (EX-101.SCH) — 3KB
• viri-20240618_lab.xml (EX-101.LAB) — 16KB
• viri-20240618_pre.xml (EX-101.PRE) — 10KB
• viri-20240618x8k_htm.xml (XML) — 5KB

07

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 18, 2024, Virios Therapeutics, Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting"). Present at the Annual Meeting in person or by proxy were holders of 8,699,494 shares of common stock of the Company, representing 45.17% of the voting power of the shares of common stock of the Company as of the close of business on April 23, 2024, the record date for the Annual Meeting, and constituting a quorum for the transaction of business. All matters voted upon at the Annual Meeting were approved with the required votes. The matters that were voted upon at the Annual Meeting, and the number of votes cast for, withheld or against, as well as the number of abstentions and broker non-votes, as to each such matter are set forth below. 1. Election of Directors. The following six nominees were elected to serve as directors of the Company, with the following votes tabulated: For Withheld Broker Non-Vote Richard Burch 3,201,273 205,492 5,292,729 Abel De La Rosa, Ph.D. 2,440,247 966,518 5,292,729 Greg Duncan 3,183,237 223,528 5,292,729 David Keefer 3,198,840 207,925 5,292,729 John C. Thomas, Jr. 3,201,528 205,237 5,292,729 Richard J. Whitley, M.D. 1,964,627 1,442,138 5,292,729 2. Ratification of the appointment of FORVIS, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. The appointment of FORVIS, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified, with the following votes tabulated: For Against Abstain Broker Non-Vote 8,347,686 241,056 110,752 — 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VIRIOS THERAPEUTICS, INC. By: /s/ Angela Walsh Name: Angela Walsh Title: Senior Vice President of Finance, Corporate Secretary and Treasurer June 20, 2024 3

View Full Filing

View this 8-K filing on SEC EDGAR